Nasus Pharma LtdNSRX
Price (close)
$3.48
Market cap
$40.8M
P/E
—
Revenue (FY)
$1.2B
Net income
-$5.9M
Dividend yield
—
1-year total return
-56.8%
Net margin
-0.5%
Revenue growth
—
Debt / equity
—
What Nasus Pharma Ltd does.
are a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical, since the nose
is lined up with a very rich vascular bed enabling quick drug absorption. We are developing a unique PBI technology with a specialized
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | — | — | $1.2B |
| Net income | — | -$1.1M | -$1.5M | -$5.9M |
| Free cash flow | — | — | — | -$4.9M |
More on NSRX.
- Nasus Pharma Ltd summary
- Nasus Pharma Ltd financial statements
- Nasus Pharma Ltd key metrics
- Nasus Pharma Ltd health scores and style box
- Nasus Pharma Ltd earnings
- Nasus Pharma Ltd dividends
- Nasus Pharma Ltd valuation
- Nasus Pharma Ltd ownership and insiders
- Nasus Pharma Ltd peers
Figures from Nasus Pharma Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.